The post MLB Sees Dramatic Drop In PED Suspensions appeared on BitcoinEthereumNews.com. Performance enhancing drugs in Major League Baseball was once a regular headline story, but over several years, there has been a significant decline in PED suspensions and players seeking therapeutic use exemptions. getty Once a burning issue for Major League Baseball, the number of suspensions for players using performance-enhancing drugs – as well as therapeutic use exemptions for banned substances – has dropped dramatically in recent years. An annual report for 2025 shows that trend continuing. If you don’t recall Alex Sanchez of the Tampa Bay Rays in 2005, you’d be forgiven. But Sanchez has a unique place in the history of Major League Baseball. On January 3, 2005, he became the first player in history suspended for a violation of MLB’s drug testing policy, serving a 10-game suspension. In the first year of the Major League Drug Prevention and Treatment Program, which was reached between MLB and the MLB Players Association, a total of 12 players were suspended for PEDs. It would not be until the Biogenesis scandal of 2013 that the likes of Alex Rodriguez, Nelson Cruz, Ryan Braun, Jhonny Peralta, and more would push MLB PED suspensions to a historical high of 16. The specter of performance-enhancing substances will never leave the sport, but in recent years, there has been a significant decline in not just suspensions, but also in the allowance of therapeutic use exemptions (TUEs) for the use of what would usually be banned substances. Each year, MLB and the MLBPA release an annual report on drug testing in the league. The report is issued by an Independent Program Administrator; this year, Thomas M. Martin, Ph.D. For 2025, the total number of drug tests that were conducted totaled 11,700. Of those, 9.400 were urine samples. The number of dried blood spot samples that were collected… The post MLB Sees Dramatic Drop In PED Suspensions appeared on BitcoinEthereumNews.com. Performance enhancing drugs in Major League Baseball was once a regular headline story, but over several years, there has been a significant decline in PED suspensions and players seeking therapeutic use exemptions. getty Once a burning issue for Major League Baseball, the number of suspensions for players using performance-enhancing drugs – as well as therapeutic use exemptions for banned substances – has dropped dramatically in recent years. An annual report for 2025 shows that trend continuing. If you don’t recall Alex Sanchez of the Tampa Bay Rays in 2005, you’d be forgiven. But Sanchez has a unique place in the history of Major League Baseball. On January 3, 2005, he became the first player in history suspended for a violation of MLB’s drug testing policy, serving a 10-game suspension. In the first year of the Major League Drug Prevention and Treatment Program, which was reached between MLB and the MLB Players Association, a total of 12 players were suspended for PEDs. It would not be until the Biogenesis scandal of 2013 that the likes of Alex Rodriguez, Nelson Cruz, Ryan Braun, Jhonny Peralta, and more would push MLB PED suspensions to a historical high of 16. The specter of performance-enhancing substances will never leave the sport, but in recent years, there has been a significant decline in not just suspensions, but also in the allowance of therapeutic use exemptions (TUEs) for the use of what would usually be banned substances. Each year, MLB and the MLBPA release an annual report on drug testing in the league. The report is issued by an Independent Program Administrator; this year, Thomas M. Martin, Ph.D. For 2025, the total number of drug tests that were conducted totaled 11,700. Of those, 9.400 were urine samples. The number of dried blood spot samples that were collected…

MLB Sees Dramatic Drop In PED Suspensions

2025/12/03 21:41

Performance enhancing drugs in Major League Baseball was once a regular headline story, but over several years, there has been a significant decline in PED suspensions and players seeking therapeutic use exemptions.

getty

Once a burning issue for Major League Baseball, the number of suspensions for players using performance-enhancing drugs – as well as therapeutic use exemptions for banned substances – has dropped dramatically in recent years. An annual report for 2025 shows that trend continuing.

If you don’t recall Alex Sanchez of the Tampa Bay Rays in 2005, you’d be forgiven. But Sanchez has a unique place in the history of Major League Baseball. On January 3, 2005, he became the first player in history suspended for a violation of MLB’s drug testing policy, serving a 10-game suspension. In the first year of the Major League Drug Prevention and Treatment Program, which was reached between MLB and the MLB Players Association, a total of 12 players were suspended for PEDs. It would not be until the Biogenesis scandal of 2013 that the likes of Alex Rodriguez, Nelson Cruz, Ryan Braun, Jhonny Peralta, and more would push MLB PED suspensions to a historical high of 16.

The specter of performance-enhancing substances will never leave the sport, but in recent years, there has been a significant decline in not just suspensions, but also in the allowance of therapeutic use exemptions (TUEs) for the use of what would usually be banned substances.

Each year, MLB and the MLBPA release an annual report on drug testing in the league. The report is issued by an Independent Program Administrator; this year, Thomas M. Martin, Ph.D.

For 2025, the total number of drug tests that were conducted totaled 11,700. Of those, 9.400 were urine samples. The number of dried blood spot samples that were collected and analyzed for the presence of human growth hormone (hGH) was 2,300.

Of those tests, two resulted in adverse findings that led to suspensions. In all cases, players are retested if there are adverse findings. Should the findings remain and fall under the substances that result in suspension, a player can appeal the suspension. Therefore, when a suspension is announced, it is a considerable period of time after the player tests positive for PEDs.

For 2025, there were two players suspended for violating the drug program:

On May 18th, José Alvarado received an 80-game suspension without pay after testing positive for exogenous Testosterone. On May 31st, Jurickson Profar received an 80-game suspension without pay after testing positive for Chorionic Gonadotrophin (hCG). In both cases, the suspensions were for performance-enhancing substances.

Therapeutic Use Exemptions For Otherwise Banned Substances

The league and MLBPA have allowed a system in which players, through a doctor’s care, and apply for what is called a Therapeutic Use Exemption, or TUEs. The TUEs is granted after comprehensive medical documentation to prove the medical need for the medication and demonstrate that the treatment only returns the athlete to a normal level of health, rather than providing an unfair advantage. In the vast majority of the TUEs granted each year, the exemption is made for Attention Deficit Hyperactivity Disorder (ADHD) medications. These medications are often amphetamine derivatives, and given that amphetamines are banned in MLB, the player would need an exemption to use such meds to address ADHD.

In years past, the number of ADHD TUEs has reached over 100, which raised the question as to whether there was a fundamental loophole in the drug testing program.

But over the years, these numbers have declined dramatically. For 2025, there was a total of 57 TUEs granted, with 54 for ADHD, along with one each granted for hypertension, sleep disorder, and hormone function. In all cases, the players granted TUEs are not released in the annual report. The drug testing program does not allow for therapeutic use exemptions for human growth hormone.

The 57 total therapeutic use exemptions in 2025 is a -37% drop from the 91 granted in 2020, and shows the drop over just the past six years. While there will likely never be a day when there are no suspensions and no therapeutic use exemptions, for now, at least within the drug program, Major League Baseball is about as free from PEDs as it may ever be.

The table below shows the number of PED suspensions, the total number of therapeutic use exemptions, and the number of those that are ADHD related from 2020 to 2025.

Graphical representation of MLB drug suspension, TUEs, and those that are for ADHD

Maury Brown

Source: https://www.forbes.com/sites/maurybrown/2025/12/03/mlb-sees-dramatic-drop-in-ped-suspensions/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

China Launches Cross-Border QR Code Payment Trial

China Launches Cross-Border QR Code Payment Trial

The post China Launches Cross-Border QR Code Payment Trial appeared on BitcoinEthereumNews.com. Key Points: Main event involves China initiating a cross-border QR code payment trial. Alipay and Ant International are key participants. Impact on financial security and regulatory focus on illicit finance. China’s central bank, led by Deputy Governor Lu Lei, initiated a trial of a unified cross-border QR code payment gateway with Alipay and Ant International as participants. This pilot addresses cross-border fund risks, aiming to enhance financial security amid rising money laundering through digital channels, despite muted crypto market reactions. China’s Cross-Border Payment Gateway Trial with Alipay The trial operation of a unified cross-border QR code payment gateway marks a milestone in China’s financial landscape. Prominent entities such as Alipay and Ant International are at the forefront, participating as the initial institutions in this venture. Lu Lei, Deputy Governor of the People’s Bank of China, highlighted the systemic risks posed by increased cross-border fund flows. Changes are expected in the dynamics of digital transactions, potentially enhancing transaction efficiency while tightening regulations around illicit finance. The initiative underscores China’s commitment to bolstering financial security amidst growing global fund movements. “The scale of cross-border fund flows is expanding, and the frequency is accelerating, providing opportunities for risks such as cross-border money laundering and terrorist financing. Some overseas illegal platforms transfer funds through channels such as virtual currencies and underground banks, creating a ‘resonance’ of risks at home and abroad, posing a challenge to China’s foreign exchange management and financial security.” — Lu Lei, Deputy Governor, People’s Bank of China Bitcoin and Impact of China’s Financial Initiatives Did you know? China’s latest initiative echoes the Payment Connect project of June 2025, furthering real-time cross-boundary remittances and expanding its influence on global financial systems. As of September 17, 2025, Bitcoin (BTC) stands at $115,748.72 with a market cap of $2.31 trillion, showing a 0.97%…
Share
BitcoinEthereumNews2025/09/18 05:28